Reading Time: 6 minutes In July 2020 Everything ALS, a team of patient advocates, medical professionals, entrepreneurs, computational biologists and medical students based in the USA, hosted a virtual
Reading Time: 2 minutes This week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Reading Time: 3 minutes At last year’s International Symposium on ALS/MND in Perth, Australia, Professor Jeffrey Iliff talked about the glymphatic system (C1 in abstract book) – a series
Reading Time: 5 minutes Guest researcher blog post written by Matthew Nolan. My name is Matthew, I’m currently a post-doctoral researcher at Massachusetts General Hospital and Harvard Medical School in
Reading Time: 4 minutes A systematic review of existing scientific literature, performed by a team of researchers led by Dr Arpan Mehta, MRC/MND Association Lady Edith Wolfson Clinical Fellow
Reading Time: 3 minutes Guest researcher blog post written by Darija Šoltić. Originally from Croatia, I came to the UK to do my PhD in neuroscience, where I worked
Reading Time: 3 minutes A recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug
Reading Time: 4 minutes Guest researcher blog post: My name is Sophie Nyberg and I am a neuroscientist currently working in the Lighthouse COVID-19 testing labs in Alderley Park,
Reading Time: 5 minutes Last Thursday marked an exciting milestone in the search for effective therapies for MND as full results from the early-phase 1/2 trial of Biogen’s tofersen
Reading Time: 4 minutes Although ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in